Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 6697 to 6701 of 6701 entries
Sorted by: Best Match Show Resources per page
Relationship between GLIM criteria and disease-specific symptoms and its impact on 5-year survival of esophageal cancer patients.

Clinical nutrition (Edinburgh, Scotland)

Okada G, Matsumoto Y, Habu D, Matsuda Y, Lee S, Osugi H.
PMID: 34455266
Clin Nutr. 2021 Sep;40(9):5072-5078. doi: 10.1016/j.clnu.2021.08.008. Epub 2021 Aug 21.

BACKGROUND & AIMS: Malnutrition is common in patients with esophageal cancer, which affects their prognosis. The global leadership initiative on malnutrition (GLIM) criteria was recently proposed as the world's first diagnostic criteria for malnutrition. However, the association between esophageal...

Cite
Okada G, Matsumoto Y, Habu D, et al. Relationship between GLIM criteria and disease-specific symptoms and its impact on 5-year survival of esophageal cancer patients. Clin Nutr. 2021;40(9):5072-5078doi: 10.1016/j.clnu.2021.08.008.
Okada, G., Matsumoto, Y., Habu, D., Matsuda, Y., Lee, S., & Osugi, H. (2021). Relationship between GLIM criteria and disease-specific symptoms and its impact on 5-year survival of esophageal cancer patients. Clinical nutrition (Edinburgh, Scotland), 40(9), 5072-5078. https://doi.org/10.1016/j.clnu.2021.08.008
Okada, Genya, et al. "Relationship between GLIM criteria and disease-specific symptoms and its impact on 5-year survival of esophageal cancer patients." Clinical nutrition (Edinburgh, Scotland) vol. 40,9 (2021): 5072-5078. doi: https://doi.org/10.1016/j.clnu.2021.08.008
Okada G, Matsumoto Y, Habu D, Matsuda Y, Lee S, Osugi H. Relationship between GLIM criteria and disease-specific symptoms and its impact on 5-year survival of esophageal cancer patients. Clin Nutr. 2021 Sep;40(9):5072-5078. doi: 10.1016/j.clnu.2021.08.008. Epub 2021 Aug 21. PMID: 34455266.
Copy Download .nbib Format: NLM
Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment.

Respiratory medicine

Fukushima K, Kitada S, Matsumoto Y, Komukai S, Kuge T, Kawasaki T, Matsuki T, Motooka D, Tsujino K, Miki M, Miki K, Nakamura S, Kida H.
PMID: 34455309
Respir Med. 2021 Oct;187:106585. doi: 10.1016/j.rmed.2021.106585. Epub 2021 Aug 26.

BACKGROUND: No objective serum biomarkers of disease course or treatment outcome of Mycobacterium avium complex lung disease (MAC-LD) presently exist. Serum IgA antibody levels against the glycopeptidolipid (GPL) core have good diagnostic accuracy for MAC-LD. However, their usefulness for...

Cite
Fukushima K, Kitada S, Matsumoto Y, et al. Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment. Respir Med. 2021;187:106585doi: 10.1016/j.rmed.2021.106585.
Fukushima, K., Kitada, S., Matsumoto, Y., Komukai, S., Kuge, T., Kawasaki, T., Matsuki, T., Motooka, D., Tsujino, K., Miki, M., Miki, K., Nakamura, S., & Kida, H. (2021). Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment. Respiratory medicine, 187106585. https://doi.org/10.1016/j.rmed.2021.106585
Fukushima, Kiyoharu, et al. "Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment." Respiratory medicine vol. 187 (2021): 106585. doi: https://doi.org/10.1016/j.rmed.2021.106585
Fukushima K, Kitada S, Matsumoto Y, Komukai S, Kuge T, Kawasaki T, Matsuki T, Motooka D, Tsujino K, Miki M, Miki K, Nakamura S, Kida H. Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment. Respir Med. 2021 Oct;187:106585. doi: 10.1016/j.rmed.2021.106585. Epub 2021 Aug 26. PMID: 34455309.
Copy Download .nbib Format: NLM
Direct platelet adhesion potentiates group 2 innate lymphoid cell functions.

Allergy

Orimo K, Tamari M, Takeda T, Kubo T, Rückert B, Motomura K, Sugiyama H, Yamada A, Saito K, Arae K, Kuriyama M, Hara M, Soyka MB, Ikutani M, Yamaguchi S, Morimoto N, Nakabayashi K, Hata K, Matsuda A, Akdis CA, Sudo K, Saito H, Nakae S, Tamaoki J, Tagaya E, Matsumoto K, Morita H.
PMID: 34402091
Allergy. 2021 Aug 17; doi: 10.1111/all.15057. Epub 2021 Aug 17.

BACKGROUND: Platelets are thought to be involved in the pathophysiology of asthma, presumably through direct adhesion to inflammatory cells, including group 2 innate lymphoid cells (ILC2s). Here, we tried to elucidate the effects of platelet adhesion to ILC2s in...

Cite
Orimo K, Tamari M, Takeda T, et al. Direct platelet adhesion potentiates group 2 innate lymphoid cell functions. Allergy. 2021;doi: 10.1111/all.15057.
Orimo, K., Tamari, M., Takeda, T., Kubo, T., Rückert, B., Motomura, K., Sugiyama, H., Yamada, A., Saito, K., Arae, K., Kuriyama, M., Hara, M., Soyka, M. B., Ikutani, M., Yamaguchi, S., Morimoto, N., Nakabayashi, K., Hata, K., Matsuda, A., Akdis, C. A., Sudo, K., Saito, H., Nakae, S., Tamaoki, J., Tagaya, E., Matsumoto, K., & Morita, H. (2021). Direct platelet adhesion potentiates group 2 innate lymphoid cell functions. Allergy, . https://doi.org/10.1111/all.15057
Orimo, Keisuke, et al. "Direct platelet adhesion potentiates group 2 innate lymphoid cell functions." Allergy vol. (2021). doi: https://doi.org/10.1111/all.15057
Orimo K, Tamari M, Takeda T, Kubo T, Rückert B, Motomura K, Sugiyama H, Yamada A, Saito K, Arae K, Kuriyama M, Hara M, Soyka MB, Ikutani M, Yamaguchi S, Morimoto N, Nakabayashi K, Hata K, Matsuda A, Akdis CA, Sudo K, Saito H, Nakae S, Tamaoki J, Tagaya E, Matsumoto K, Morita H. Direct platelet adhesion potentiates group 2 innate lymphoid cell functions. Allergy. 2021 Aug 17; doi: 10.1111/all.15057. Epub 2021 Aug 17. PMID: 34402091.
Copy Download .nbib Format: NLM
NOD2 Genotypes Affect the Symptoms and Mortality in the Porcine Circovirus 2-Spreading Pig Population.

Genes

Suzuki K, Shinkai H, Yoshioka G, Matsumoto T, Tanaka J, Hayashi N, Kitazawa H, Uenishi H.
PMID: 34573406
Genes (Basel). 2021 Sep 16;12(9). doi: 10.3390/genes12091424.

The nucleotide oligomerization domain (NOD)-like receptor 2 (NOD2) is an intracellular pattern recognition receptor that detects components of peptidoglycans from bacterial cell walls. NOD2 regulates bowel microorganisms, provides resistance against infections such as diarrhea, and reduces the risk of...

Cite
Suzuki K, Shinkai H, Yoshioka G, et al. NOD2 Genotypes Affect the Symptoms and Mortality in the Porcine Circovirus 2-Spreading Pig Population. Genes (Basel). 2021;12(9)doi: 10.3390/genes12091424.
Suzuki, K., Shinkai, H., Yoshioka, G., Matsumoto, T., Tanaka, J., Hayashi, N., Kitazawa, H., & Uenishi, H. (2021). NOD2 Genotypes Affect the Symptoms and Mortality in the Porcine Circovirus 2-Spreading Pig Population. Genes, 12(9), . https://doi.org/10.3390/genes12091424
Suzuki, Kasumi, et al. "NOD2 Genotypes Affect the Symptoms and Mortality in the Porcine Circovirus 2-Spreading Pig Population." Genes vol. 12,9 (2021). doi: https://doi.org/10.3390/genes12091424
Suzuki K, Shinkai H, Yoshioka G, Matsumoto T, Tanaka J, Hayashi N, Kitazawa H, Uenishi H. NOD2 Genotypes Affect the Symptoms and Mortality in the Porcine Circovirus 2-Spreading Pig Population. Genes (Basel). 2021 Sep 16;12(9). doi: 10.3390/genes12091424. PMID: 34573406; PMCID: PMC8469532.
Copy Download .nbib Format: NLM
Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis.

Journal of the American Heart Association

Uchiyama S, Toyoda K, Omae K, Saita R, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, Matsumoto M, Tominaga T, Tomimoto H, Terayama Y, Yasuda S, Yamaguchi T.
PMID: 34622679
J Am Heart Assoc. 2021 Oct 19;10(20):e022575. doi: 10.1161/JAHA.121.022575. Epub 2021 Oct 08.

Background Long-term benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) for the prevention of recurrent stroke has not been established in patients with intracranial arterial stenosis. We compared the efficacy and safety of DAPT with cilostazol...

Cite
Uchiyama S, Toyoda K, Omae K, et al. Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis. J Am Heart Assoc. 2021;10(20):e022575doi: 10.1161/JAHA.121.022575.
Uchiyama, S., Toyoda, K., Omae, K., Saita, R., Kimura, K., Hoshino, H., Sakai, N., Okada, Y., Tanaka, K., Origasa, H., Naritomi, H., Houkin, K., Yamaguchi, K., Isobe, M., Minematsu, K., Matsumoto, M., Tominaga, T., Tomimoto, H., Terayama, Y., Yasuda, S., & Yamaguchi, T. (2021). Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis. Journal of the American Heart Association, 10(20), e022575. https://doi.org/10.1161/JAHA.121.022575
Uchiyama, Shinichiro, et al. "Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis." Journal of the American Heart Association vol. 10,20 (2021): e022575. doi: https://doi.org/10.1161/JAHA.121.022575
Uchiyama S, Toyoda K, Omae K, Saita R, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, Matsumoto M, Tominaga T, Tomimoto H, Terayama Y, Yasuda S, Yamaguchi T. Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis. J Am Heart Assoc. 2021 Oct 19;10(20):e022575. doi: 10.1161/JAHA.121.022575. Epub 2021 Oct 08. PMID: 34622679; PMCID: PMC8751870.
Copy Download .nbib Format: NLM
Showing 6697 to 6701 of 6701 entries